This content is only available within our institutional offering.
31 Jul 2019
Pharmaceuticals: Lilly: Read-across from Q2 results for European companies
Novartis AG (0QLR:LON), 0 | Roche Holding Ltd Dividend Right Cert. (RHO5:ETR), 0 | Merck KGaA (MRCK:WBO), 0 | Sanofi (SANO:WBO), 0 | AstraZeneca PLC (AZN:LON), 11,224 | GSK plc (GSK:LON), 1,652 | Ipsen SA (IPN:WBO), 0 | Novo Nordisk A/S Class B (NNO2:WBO), 0 | UCB S.A. (UCB:WBO), 0 | Bayer AG (BAYN:WBO), 0 | Basilea Pharmaceutica AG (0QNA:LON), 0
Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Pharmaceuticals: Lilly: Read-across from Q2 results for European companies
Novartis AG (0QLR:LON), 0 | Roche Holding Ltd Dividend Right Cert. (RHO5:ETR), 0 | Merck KGaA (MRCK:WBO), 0 | Sanofi (SANO:WBO), 0 | AstraZeneca PLC (AZN:LON), 11,224 | GSK plc (GSK:LON), 1,652 | Ipsen SA (IPN:WBO), 0 | Novo Nordisk A/S Class B (NNO2:WBO), 0 | UCB S.A. (UCB:WBO), 0 | Bayer AG (BAYN:WBO), 0 | Basilea Pharmaceutica AG (0QNA:LON), 0
- Published:
31 Jul 2019 -
Author:
Eric Le Berrigaud -
Pages:
3
Pharmaceuticals
Lilly: Read-across from Q2 results for European companies
The profound change in mix in diabetes continues
Talz on par with Cosentyx in psoriasis?
Verzenio clearly ahead of Kisqali and moving into HER2+ BC?